Citigroup
ESPR

Citigroup’s Esperion Therapeutics ESPR Stock Holding History

Citigroup’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,700
Closed -$408K – 6572
2020
Q4 		$408K Buy
15,700
+3,500
+29% +$105K ﹤0.01% 4383
2020
Q3 		$453K Buy
12,200
+5,000
+69% +$198K ﹤0.01% 3934
2020
Q2 		$369K Sell
7,200
-800
-10% -$33.5K ﹤0.01% 4532
2020
Q1 		$252K Sell
8,000
-12,400
-61% -$654K ﹤0.01% 4534
2019
Q4 		$1.22M Buy
20,400
+6,200
+44% +$279K ﹤0.01% 3556
2019
Q3 		$521K Sell
14,200
-15,700
-53% -$622K ﹤0.01% 4301
2019
Q2 		$1.39M Sell
29,900
-5,100
-15% -$240K ﹤0.01% 3245
2019
Q1 		$1.41M Buy
35,000
+5,700
+19% +$256K ﹤0.01% 3034
2018
Q4 		$1.35M Buy
29,300
+11,800
+67% +$569K ﹤0.01% 3089
2018
Q3 		$776K Sell
17,500
-22,600
-56% -$1.04M ﹤0.01% 3775
2018
Q2 		$1.57M Buy
40,100
+30,600
+322% +$1.55M ﹤0.01% 2909
2018
Q1 		$687K Sell
9,500
-600
-6% -$44.1K ﹤0.01% 3652
2017
Q4 		$665K Sell
10,100
-3,800
-27% -$205K ﹤0.01% 3788
2017
Q3 		$697K Sell
13,900
-100
-0.7% -$4.82K ﹤0.01% 3752
2017
Q2 		$648K Buy
14,000
+6,700
+92% +$246K ﹤0.01% 3750
2017
Q1 		$258K Buy
7,300
+2,900
+66% +$66.4K ﹤0.01% 4452
2016
Q4 		$55K Sell
4,400
-4,200
-49% -$50K ﹤0.01% 6097
2016
Q3 		$119K Sell
8,600
-1,200
-12% -$13.6K ﹤0.01% 5081
2016
Q2 		$97K Buy
9,800
+8,000
+444% +$133K ﹤0.01% 5099
2016
Q1 		$30K Sell
1,800
-2,200
-55% -$35.4K ﹤0.01% 6353
2015
Q4 		$89K Sell
4,000
-4,200
-51% -$106K ﹤0.01% 5463
2015
Q3 		$193K Buy
+8,200
New +$515K ﹤0.01% 4521

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Citigroup's ESPR Position: Q2 2026 in Review

Citigroup increased its Esperion Therapeutics (ESPR) stake by 188% in Q2 2026, buying an estimated $701K and bringing the position to 384,261 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3308.

Citigroup first reported a position in ESPR in Q3 2013 and has held it in 52 quarters since. The position peaked at $11.1M in Q4 2018. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Citigroup held 384,261 shares of Esperion Therapeutics worth $1.21M as of Q2 2026.
  • Citigroup bought 250,665 Esperion Therapeutics shares in Q2 2026, an estimated $701K.
  • Esperion Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3308 holding.
  • Citigroup first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 52 quarters since.
  • Citigroup's Esperion Therapeutics position peaked at $11.1M in Q4 2018.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.